Delivery Order SPE2DB22D9367-SPE2DB24FSZ59

Award Date 9/9/24
Potential Completion Date 9/30/24
Potential Value $28K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,327.42 contract is for the delivery of 160 mg vials of the oncology drug Kadcyla. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $20,478.24, is for the delivery of 100 mg vials of the oncology drug Kadcyla. This delivery order is issued under a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA, which allows the agency to place orders for a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense, to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $20,519.60, is for the delivery of 160 mg vials of the oncology drug Kadcyla. The contract has no set-aside designation and is a firm fixed-price delivery order awarded under DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract (IDC) with the DLA, which provides a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $12,798.90, is for the delivery of 100 mg vials of the drug Kadcyla. The delivery order is part of a larger indefinite delivery contract (IDC) with DLA, valued at up to $499,999,999, that allows the agency to issue orders for a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This contract is for the delivery of 100 mg vials of the oncology drug Kadcyla. The contract has a completion date of July 5, 2024 and uses a Firm Fixed Price pricing structure. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $34,476.80 contract is for the provision of 160 mg vials of the oncology medication Kadcyla. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC enables the DLA to issue...
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $26,654.84, is for the delivery of 160 mg vials of the oncology drug Kadcyla. The contract is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $24,623.52, is for the delivery of the oncology drug Kadcyla 160 mg vials to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,915.24, is for the delivery of 100 mg vials of the cancer drug Kadcyla. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at $499,999,999 and valid through November 2026. The IDC...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,731.36 firm fixed-price contract is for the supply of 160 mg vials of the cancer drug Kadcyla. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a comprehensive range of...
  • SPE2DB22D9367
    Indefinite Delivery Contract
  • SPE2DB22D9367-SPE2DB24FSZ59
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, worth $27,670.50, is a firm fixed-price delivery order for 100 mg vials of the oncology drug Kadcyla. The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which covers a comprehensive range of pharmaceutical products to support the medical supply needs of the U.S. Department of Defense. This contract has no set-aside designation.

Generated 12/9/24, 1:51 PM